{"id":"efavirenz-qd-zidovudine-lamivudine-bid","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Dizziness and CNS effects (efavirenz)"},{"rate":"15-20","effect":"Rash"},{"rate":"10-15","effect":"Nausea"},{"rate":"5-10","effect":"Anemia (zidovudine)"},{"rate":"5-10","effect":"Peripheral neuropathy (lamivudine/zidovudine)"},{"rate":null,"effect":"Lipodystrophy"},{"rate":null,"effect":"Hepatotoxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Efavirenz binds directly to HIV reverse transcriptase and inhibits its activity, while zidovudine and lamivudine are nucleoside analogs that are incorporated into the growing DNA chain during reverse transcription, causing chain termination. Together, these three agents provide complementary inhibition of reverse transcriptase through different mechanisms, reducing the likelihood of resistance development.","oneSentence":"This combination uses efavirenz (a non-nucleoside reverse transcriptase inhibitor) plus zidovudine and lamivudine (nucleoside reverse transcriptase inhibitors) to suppress HIV replication by blocking reverse transcriptase at multiple points.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:10:40.132Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection"}]},"trialDetails":[{"nctId":"NCT03178084","phase":"PHASE3","title":"Effects of Maraviroc vs. Efavirenz on CD4/CD8 Ratio","status":"COMPLETED","sponsor":"Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal","startDate":"2014-10-15","conditions":"HIV/AIDS","enrollment":721},{"nctId":"NCT00098293","phase":"PHASE3","title":"Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2004-11","conditions":"HIV-1","enrollment":916},{"nctId":"NCT00256828","phase":"PHASE4","title":"Once a Day (QD) - Twice a Day (BID) Clinical Trial: Didanosine, Lamivudine and Efavirenz Versus Zidovudine, Lamivudine and Efavirenz in the Starting Treatment of HIV","status":"COMPLETED","sponsor":"Clinical Trial Agency of HIV Study Group","startDate":"2004-06","conditions":"HIV Infections","enrollment":360},{"nctId":"NCT00005018","phase":"PHASE4","title":"Safety and Effectiveness of a Combination Anti-HIV Drug Treatment","status":"COMPLETED","sponsor":"Glaxo Wellcome","startDate":"1999-07","conditions":"HIV Infections","enrollment":150},{"nctId":"NCT00011895","phase":"PHASE4","title":"Safety and Effectiveness of TRIZIVIR (Abacavir/Lamivudine/Zidovudine) With Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs","status":"UNKNOWN","sponsor":"GlaxoSmithKline","startDate":"2001-02","conditions":"HIV Infections","enrollment":400},{"nctId":"NCT00004585","phase":"PHASE4","title":"A Study of the Safety and Effectiveness of Combination Anti-HIV Therapy in HIV-Infected Adults","status":"COMPLETED","sponsor":"Glaxo Wellcome","startDate":"1999-10","conditions":"HIV Infections","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Efavirenz QD + Zidovudine/Lamivudine BID","genericName":"Efavirenz QD + Zidovudine/Lamivudine BID","companyName":"Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal","companyId":"fundacion-para-la-investigacion-biomedica-del-hospital-universitario-ramon-y-caj","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses efavirenz (a non-nucleoside reverse transcriptase inhibitor) plus zidovudine and lamivudine (nucleoside reverse transcriptase inhibitors) to suppress HIV replication by blocking reverse transcriptase at multiple points. Used for HIV-1 infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}